A 450% revenue beat, a 20%+ gain: the biotech our AI models picked first
Viridian Therapeutics (VRDN) reported Q3 2026 revenue of $25.75M, beating consensus by 450.2%, driven by its FDA-approved thyroid eye disease treatment. Shares rose 9.09% premarket. The company has $955.2M in cash and expects a BLA submission for another drug in Q1 2027. Investing.com's AI models picked VRDN in November, and shares are up 20.92% since then.
How this was made
The 30-second read
Why it matters
The earnings surprise validates the AI model's selection, potentially boosting confidence in similar picks.
Market read
VRDN's earnings beat and pre‑market rally present a short‑term trading opportunity within the biotech space.
What to watch
High cash burn and reliance on a single product could limit upside if sales plateau.
Background
Investing.com AI‑powered stock picker highlighted VRDN before its earnings release; members saw a 20% gain since the pick.
Ticker impact
Q3 2026 revenue of $25.75M beat consensus $4.68M (450% beat) and shares rose 9.09% pre‑market.
likely upward pressure as traders price in the revenue beat and commercial launch momentum
The surprise revenue magnitude and 9% pre‑market rally indicate fresh buying interest; no contrary news present.
Market effects
Biotech sector may see increased investor focus on companies with recent FDA approvals.
US small‑cap biotech segment gains modest attention.
Limited to biotech investors; no broad market shift expected.
Counterpoint
The revenue beat may be a one‑off; long‑term growth depends on sustained product uptake.
Key entities
- companyViridian Therapeutics
Small‑cap biotech with FDA‑approved thyroid eye disease treatment.

